You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|
|---|---|
| Published in |
Lancet Oncology, January 2014
|
| DOI | 10.1016/s1470-2045(13)70586-2 |
| Pubmed ID | |
| Authors |
Martin Reck, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Claudia-Nanette Gann, José Barrueco, Birgit Gaschler-Markefski, Silvia Novello, for the LUME-Lung 1 Study Group |
| Abstract |
The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). |
X Demographics
The data shown below were collected from the profiles of 37 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 22% |
| United Kingdom | 3 | 8% |
| Japan | 1 | 3% |
| Canada | 1 | 3% |
| Netherlands | 1 | 3% |
| Argentina | 1 | 3% |
| France | 1 | 3% |
| India | 1 | 3% |
| Turkey | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 17 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 65% |
| Scientists | 6 | 16% |
| Practitioners (doctors, other healthcare professionals) | 6 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 540 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| France | 2 | <1% |
| United States | 2 | <1% |
| Ethiopia | 1 | <1% |
| Netherlands | 1 | <1% |
| India | 1 | <1% |
| Germany | 1 | <1% |
| Spain | 1 | <1% |
| Brazil | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 528 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 101 | 19% |
| Other | 70 | 13% |
| Student > Ph. D. Student | 56 | 10% |
| Student > Bachelor | 54 | 10% |
| Student > Master | 50 | 9% |
| Other | 82 | 15% |
| Unknown | 127 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 250 | 46% |
| Agricultural and Biological Sciences | 36 | 7% |
| Biochemistry, Genetics and Molecular Biology | 30 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 4% |
| Nursing and Health Professions | 13 | 2% |
| Other | 47 | 9% |
| Unknown | 142 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 59. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2023.
All research outputs
#729,657
of 25,837,817 outputs
Outputs from Lancet Oncology
#910
of 6,943 outputs
Outputs of similar age
#7,468
of 322,487 outputs
Outputs of similar age from Lancet Oncology
#15
of 129 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,943 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 129 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.